An advocacy victory: final USPSTF cervical cancer screening recommendations revised to include cotesting option

Diane Davis Davey*, Robert A. Goulart, Ritu Nayar

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Scopus citations


The recent reversal of the US Preventive Services Task Force decision to drop cotesting (Papicolaou test + high-risk human papillomavirus test) as an option for cervical cancer screening in women aged 30 to 65 years from their recommendations for cervical cancer screening was directly attributed to advocacy efforts by professional organizations and individuals. This communication summarizes the pathology and laboratory medicine community's role in this advocacy effort by collaboration of all major US Pathology organizations, via the Cytopathology Education and Technology consortium.

Original languageEnglish (US)
Pages (from-to)333-335
Number of pages3
JournalJournal of the American Society of Cytopathology
Issue number6
StatePublished - Nov 1 2018



  • Cervical cancer
  • Cervical cancer screening
  • Cervical cytology
  • Pap test
  • Primary HPV screening
  • USPSTF guidelines

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this